Related Experiment Video
Updated: Jul 29, 2026

Microsurgical Skills of Establishing Permanent Jugular Vein Cannulation in Rats for Serial Blood Sampling of Orally Administered Drug
Published on: December 14, 2021
Inhibiting effect of ethinylestradiol/levonorgestrel combination on microsomal enzymatic activities in rat liver and
1II Department of Histology and Embryology, Silesian Medical Academy, Katowice, Poland.
Abstract:
The aim of the study was to evaluate the effects of two therapeutic combinations of ethinylestradiol (EE) and levonorgestrel (LE), which are used in triphasic contraceptives, on the activities of drug-metabolizing enzymes in rat liver and kidney. Sexually mature female Wistar rats were given 0.03 mg EE and 0.05 mg LE, or 0.03 mg EE and 0.125 mg LE for 6 or 18 sexual cycles, i.e. for 30 or 90 days. EE/LE inhibited not only the metabolic capacity of P450, a protein which directly undergoes suicide inhibition, but also the level of rat liver cytochrome b5 (dependent on the heme pool) as well as the activities of NADPH-cytochrome P450 reductase and NADH-cytochrome b5 reductase in the liver and kidney. The majority of these effects were independent of the gestagen dose and of the duration of treatment, suggesting that estrogen is a predominant inhibiting factor in the EE/LE combination. The study has revealed differences in the enzyme activities between the liver and kidney, which may result from the fact that these organs display different sets of P450 isoforms and, therefore, their monooxygenase systems show distinct capacities to metabolize exogenous steroids.
Related Concept Videos
Hepatic Drug Excretion: Influencing Factors
Pharmacokinetics: Drug–Drug Interactions
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

